Adelene Q. Perkins - Sep 8, 2023 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC. (INFI)

Role
Director
Signature
/s/ Adelene Q. Perkins
Stock symbol
INFI
Transactions as of
Sep 8, 2023
Transactions value $
-$28,714
Form type
4
Date filed
9/12/2023, 06:20 PM
Previous filing
Jan 9, 2023
Next filing
Jan 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INFI Common Stock Options Exercise +768K +93.98% 1.59M Sep 9, 2023 Direct F1
transaction INFI Common Stock Sale -$28.7K -410K -25.87% $0.07 1.18M Sep 12, 2023 Direct F2
holding INFI Common Stock 16.4K Sep 8, 2023 401(K)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INFI Restricted Stock Unit Options Exercise $0 -768K -100% $0.00* 0 Sep 9, 2023 Common Stock 768K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date.
F2 Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person.
F3 On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023.